Amanta Healthcare Ltd. IPO: All You Need To Know

The global economy showed signs of stabilization in 2024, with GDP expanding by 3.3% as inflation eased and labor markets normalized. Within healthcare, the Indian IV fluids market has witnessed strong traction, growing from ₹29 billion in FY19 to ₹45-47 billion in FY24, driven by rising population, higher incidence of chronic diseases, and increasing adoption of IV therapy as a fast-acting treatment method. Supported by robust healthcare delivery growth and rising demand from hospitals and clinics, the industry is projected to grow at a CAGR of 9-11% over FY24-FY29, reaching ₹70-80 billion by FY29. Government spending further underpins this growth, with the Ministry of Health & Family Welfare (MoHFW) budget expanding at 10% CAGR between FY11 and FY25 and maintaining utilisation rates above 100% in recent years, aided by public-private partnerships (PPP) and the push for universal healthcare access.

Detail	Information
IPO Open Date	Sep 01, 2025
IPO Close Date	Sep 03, 2025
Price Band	₹120 – ₹126 per share
Lot Size	119 shares
Issue Size	₹1,260 million
Listing At	BSE, NSE
Tentative Listing Date	To be announced

Amanta Healthcare is a pharmaceutical company engaged in developing, manufacturing, and marketing sterile liquid products, including large and small volume parenterals (LVPs, SVPs) and medical devices. Using advanced ABFS and ISBM technologies, it offers a wide therapeutic portfolio spanning IV fluids, diluents, ophthalmic, respiratory, and irrigation solutions, along with medical devices like first-aid and eye care products. Its WHO-GMP certified facility in Hariyala, Gujarat, with four LVP and three SVP lines, is supported by formulation development and quality control labs and holds multiple international accreditations. With container sizes ranging from 2ml-1000ml and a diversified product base, Amanta delivers differentiated sterile solutions across antibiotics, antifungals, diuretics, ophthalmics, and respiratory therapies for both branded and partnering businesses.

Amanta Healthcare reported total revenue from operations of ₹2747.08 million in FY25, broadly stable compared to ₹2591.29 million in FY23. EBITDA grew to ₹610.53 million in FY25, translating into healthy margins of 22.22% versus 20.96% in FY24. Profitability improved sharply, with PAT rising nearly threefold to ₹105.01 million in FY25 from ₹36.33 million in FY24, resulting in a PAT margin of 3.86% against 1.3% in the previous year. Return ratios strengthened, with ROE improving to 12.42% in FY25 from 5.27% in FY24, while ROCE expanded to 13.72% from 12.76%. On the leverage front, the company’s debt-to-equity ratio declined to 2.02x in FY25 from 3.1x in FY24, reflecting improving balance sheet strength alongside sustained operating performance.

Objects of the issue: 

1. Capex for new SteriPort manufacturing line at Hariyala, Gujarat – INR 700 million
2. Capex for new SVP manufacturing line at Hariyala, Gujarat – INR 301.31 million
3. General Corporate Purposes

📱 Apply Online through the SMIFS ELITE App | Download now:

Experience seamless investing at your fingertips!